No Data
No Data
No Data
No Data
No Data
[Broker Focus] Tianfeng Securities maintains Luye Pharmaceutical's (02186) “buy” rating, indicating that the main types of core business have large market space
Jinwu Financial News | According to Tianfeng Securities Research Report, Luye Pharmaceutical (02186) announced 2023 results: overall operating revenue of 6.14 billion yuan in 2023, up 2.7% year on year, product sales revenue of 5.63 billion yuan, up 11.2% year on year, and net profit to mother of 533 million yuan, down 11.9% year on year. The decline in net profit is mainly due to a decrease in the share of authorized revenue. The company's overall performance was in line with expectations. The bank mentioned that subsequent sales volume of core products and progress in the research pipeline are worth looking forward to, and there is plenty of room for reasonable valuation. According to this bank, considering the outstanding advantages of the company's new products, there will be many
金吾財訊Apr 10 02:36 ET
Huaan Securities: Maintaining Luye Pharmaceutical's (02186) “Buy” Rating Rapid Growth in Sales Revenue in 2023
Huaan Securities is optimistic about the rapid release of new oncology products such as Luye Pharmaceuticals (02186) and Baituwei after they are launched.
Zhitong FinanceApr 1 03:34 ET
Changes in Hong Kong stocks | Luye Pharmaceutical (02186) fell nearly 5% in the afternoon, annual net profit fell 11.9% year-on-year, and sales revenue of oncology products fell 8%
Luye Pharmaceutical (02186) fell nearly 5% in the afternoon. As of press release, it was down 4.58% to HK$2.71, with a turnover of HK$28.295,800.
Zhitong FinanceMar 28 02:37 ET
Luye Pharmaceutical Announces 2023 Annual Results Profit attributable to shareholders of 533 million yuan, a year-on-year decrease of 11.94%
Luye Pharmaceutical (02186) announced its annual results for the year ended December 31, 2023. The group achieved revenue of 6.143 billion yuan (RMB, same below) during the period, an increase of 2.7% over the previous year; profit attributable to shareholders was 533 million yuan, a decrease of 11.94% year on year; and basic profit per share was 14.29 points.
新浪港股Mar 27 21:02 ET
Is There An Opportunity With Luye Pharma Group Ltd.'s (HKG:2186) 27% Undervaluation?
Key Insights The projected fair value for Luye Pharma Group is HK$3.88 based on 2 Stage Free Cash Flow to Equity Luye Pharma Group is estimated to be 27% undervalued based on current share price of
Simply Wall StMar 27 18:16 ET
Luye Pharmaceutical Announces 2023 Annual Results
Product sales have grown steadily, and the financial structure has been significantly optimized, Shanghai, March 27, 2024/PRNewswire/ -- On March 27, Luye Pharmaceutical Group (2186.HK) announced its 2023 annual results and business progress to date. During the reporting period, the Group's revenue was about 6.14 billion yuan, up 2.7% year on year; EBITDA was about 2.08 billion yuan, up 14.6% year on year; profit before tax was about 70 billion yuan, up 4.5% year on year. The Group's balance ratio was approximately 46.9%, down 7.6 percentage points from the previous year. Of operating income, production
PR NewswireMar 27 11:10 ET
No Data
No Data